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Abstract 
 
Objectives: Quite a number of patients diagnosed with major depression are resistant to several well 
carried-out psychopharmacological interventions. It remains unclear as to how the serotonergic system is 
implicated in the phenomenon of treatment-resistance.  
Methods: We examined the involvement of post-synaptic 5-HT2A receptors in the pathophysiology of 
treatment resistance in unipolar melancholic major depression with 123I-5-I-R91150 SPECT. 15 
antidepressant-naïve (ADN) first-episode depressed patients, 15 antidepressant-free treatment-resistant 
depressed (TRD) patients and 15 never-depressed individuals, matched for age and gender were studied.  
Results: Compared to ADN patients and healthy controls, TRD patients displayed significantly lower 5-
HT2A receptor binding index (BI) in the dorsal regions of the prefrontal and the anterior cingulate cortex. 
No significant 5-HT2A receptor BI differences between ADN patients and controls were observed.  
Conclusions: At the cortical level, 5-HT2A receptor BI does not significantly differ in first-episode 
melancholic depressed patients compared to healthy controls. This observation might imply a limited short-
term impact on the serotonergic system in first episode depression. Our results also suggest that when 
encountered with treatment resistance, the 5-HT2A receptors in the DPFC-ACC axis are significantly down-
regulated. However, whether this assumed underlying pathophysiological mechanism is due solely to 
abnormalities in the serotonergic system remains to be answered. 
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1. Introduction 
Major depression is a worldwide mental health problem affecting millions (Nemeroff 2007a). 
Unfortunately, not all depressed patients respond to the available pharmacological treatment algorithms and 
refractory depression is not uncommon (Fava 2003). It is estimated that treatment-resistance occurs in up to 
40% of depressive episodes that are adequately treated with first-line antidepressant therapy (Souery et al. 
2007). Ten percent or even more of patients suffering from major depression are resistant to several 
psychopharmacological interventions, even when adhering to treatment guidelines (Fagiolini & Kupfer 
2003; Berlim & Turecki 2007). Not surprisingly, it has been proposed that severe treatment resistance 
could be a different type of depression (Nemeroff 2007b). Furthermore, when challenged with clinical non-
response, treatment options are limited (Shelton et al. 2010; Ward & Irazoqui 2010).  
 The serotonergic system remains one of the main targets of psychotropic drug intervention to treat 
depression (Neumeister & Charney 2002). Ascending serotonergic projections arise primarily from the 
raphe nuclei in the brainstem and ‘arborize’ widely throughout cortico-subcortical structures, innervating 
forebrain and limbic areas (Hensler 2006). Prefrontal cortical serotonergic innervations have been found to 
be reduced in depressed individuals (Larisch et al. 2001; Arango et al. 2002). Being part of the G-protein 
coupled 5-HT2 serotonin receptor family, post-synaptic 5-HT2A receptors are implicated in the 
pathophysiology of many neuropsychiatric disorders including major depression, and they are implicated in 
several brain functions such as appetite control, thermoregulation, emotion, personality, cognition, ageing 
and sleep (Aghajanian & Sander-Bush 2002; Celada et al. 2004; Frokjaer et al. 2010). These receptors have 
widespread distributions throughout the cortex, with high densities in the frontal cortex (Barnes & Sharp 
1999). However, it has to be noted that discrepant results in 5-HT2A receptor research in depression have 
been reported, with some authors demonstrating 5-HT2A receptor increases, others demonstrating decreases, 
or no differences in receptor ligand binding at all (D’haenen 2004; Bhagwagar et al. 2006). Confounding 
variables such as sample size, heterogeneity, age, antidepressant drug status and suicide levels could be an 
explanation for these observed discrepancies. Nevertheless, there seems to be a growing consensus 
indicating a decreased cortical 5-HT2A receptor binding in depressed patients compared with normal 
controls (D’haenen 2001). 
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 Few studies have examined the differences in 5-HT2A receptor binding between currently 
depressed antidepressant naïve (ADN) patients, depressed patients who have been treated with 
antidepressants, and never-depressed healthy controls (Massau et al. 1997; Messa et al. 2003; Schins et al. 
2005). Although negative results are also reported (Schins et al. 2005), Messa et al (2003) found decreased 
frontal cortical 5-HT2A binding indices in symptomatic ADN patients as compared to their control group. 
They suggested that 5-HT2A receptors are reduced in depressive patients during symptomatic periods. 
However, at this point it is not clear whether these serotonergic abnormalities found in unipolar depressed 
samples are any different when encountered with treatment resistance. No studies examined the possible 
differences at the level of 5-HT2A receptor BI between untreated depressed patients and AD-free depressed 
patients who were “unsuccessfully” treated with several psychopharmacological interventions.  
In the present study, we focused on the 5-HT2A receptors in well defined gender-controlled 
homogeneous groups of unipolar depressed patients, using SPECT and the radioligand 4-amino-N-[1-[3-(4-
fluorophenoxy)propyl]-4-methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide (123I-5-I-R91150) (Terriere et 
al. 1995). As age-dependent reductions in 5-HT2A receptor binding indices in the cortex have consistently 
been reported (Baeken et al. 1998; Meltzer et al. 1998), patients and controls were also matched for age. 
Because hormonal processes seem to differ between depression subtypes (Porter & Gallagher 2006), our 
patient group consisted only of depressed patients with melancholic features. Melancholic depression is 
characterized by anhedonia, i.e., distinct quality of depressed mood, depression symptoms worse in the 
mornings, early morning awakenings, psychomotor retardation, weight loss, and excessive feelings of guilt 
(Gold & Chrousos 2002). Treatment-resistant depressed (TRD) patients had had a minimum of two 
unsuccessful treatment trials with serotonin reuptake inhibitors/ noradrenaline and serotonin reuptake 
inhibitors (SSRI/NSRI) and one failed clinical trial with a tricyclic antidepressant (TCA). TRD patients 
were tapered-off their psychotropic drugs, and all were at least medication-free for at least two weeks 
before SPECT scanning. Only when necessary TRD patients were kept on a steady dose of 
benzodiazepines.  
Firstly, in line with former research, we hypothesized that compared to never depressed-
individuals in both the currently depressed ADN patients and the treatment-resistant depressed (TRD) 
patients, 5-HT2A receptor BI would be significantly lower in all the cortical areas examined. Secondly, we 
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expected that these reductions in 5-HT2A receptor BI would be even larger in TRD patients compared to 
ADN patients. Thirdly, because in primary depression clinical symptoms and brain imaging data point to a 
functional deficit in the frontal cortical regions (Mayberg 2003), we expected that the differences in 5-HT2A 
receptor BI would be most apparent in these areas. 
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2. Materials and Methods 
2.1. Subjects 
The study was approved by the ethics committee of the University Hospital (UZBrussel) and all 
subjects gave written informed consent. As the focus of this research is treatment resistance, fifteen right-
handed unipolar melancholic TRD patients (Female:Male (F:M)= 9:6; age= 38.6±9.5y) were studied. See 
also Table 1. They were closely matched with fifteen first episode right-handed medication-free unipolar 
melancholic ADN depressed patients (F:M= 9:6; age= 36.3±9.8y) and fifteen never-depressed medication-
free healthy volunteers (F:M= 9:6; age= 37.01± 9.8y), who were included as control group. In other words, 
for each female or male TRD patient a suitable female or male ADN patient and healthy control was 
selected, matched for age as close as possible. Parts of the TRD patient and the control SPECT data were 
also used for another study, examining the treatment effects of high frequency repetitive transcranial 
magnetic stimulation in these kinds of patients (Baeken et al. 2011). According to the Diagnostic and 
Statistical Manual of Mental Disorders criteria (Diagnostic and Statistical Manual of Mental Disorders, 
Fourth edition, text revision. Washington, DC, American Psychiatric association, 2000), all patients were 
diagnosed with unipolar major depression of the melancholic subtype (ICD-9-CM code 296.23 and 
296.33). Current or past psychotic features or a history of bipolarity were considered as exclusion criteria. 
Patients with substance abuse/dependence were not included in the study. Because in post-mortem studies 
increased 5-HT2(A) receptor BI are reported in the frontal cortices of suicide victims (van Heeringen et al. 
2003), suicidal attempts during the current depressive episode were considered as an exclusion criterion. 
All participants were in good physical health. Severity of depression was assessed with the 17-item 
Hamilton Depression scale (HDRS; Hamilton 1967) by a qualified psychiatrist, unrelated to the study. All 
ADN patients were by definition drug-free in the current episode, but they were also never treated with 
antidepressants in the past. All TRD patients were considered at least stage III treatment resistant as 
described by Rush et al (2003): they had had a minimum of two unsuccessful treatment trials with an 
SSRI/NSRI and one failed clinical trial with a TCA. All unsuccessful treatment trials were carried-out at 
therapeutic antidepressant dosages for at least eight weeks. After a washout period, all TRD patients were 
free from antidepressants, neuroleptics and mood stabilizers for at least two weeks. This AD-free time 
frame is commonly used in PET/SPECT brain imaging studies examining serotonin receptors (D’haenen et 
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al., 1992; Parsey et al., 2006). All TRD patients were closely monitored by their personal physicians during 
the washout of their current psychopharmacological treatments. In agreement with the treating physician, 
when necessary TRD patients were kept on a steady dose of benzodiazepines (n=6).  
 
2.3. Scanning Procedure 
All patients received a static baseline SPECT scan. SPECT-imaging was performed with a 
Siemens MultiSPECT triple-headed gamma camera, equipped with parallel-hole medium-energy 
collimators. All subjects received oral Lugol’s solution containing 400mg of potassium iodide 15 min prior 
to injection for thyroid blockage. An average of 150MBq 123I-5-I-R91150, was manually injected. SPECT 
acquisition was performed at a minimum of 120 min after administration of the tracer. Data were collected 
from 96 angular positions over 360° in a 128x128 matrix, with a total acquisition time of 32 min. 
Reconstruction of the acquired projection images was performed using an iterative reconstruction algorithm 
(Ordered Subset Expectation Maximization, OSEM, 8 iterations, 8 subsets) and filtered with a 3D Gaussian 
using 15mm full-width at half-maximum.  
SPECT scans were automatically co-registered to a template image that was placed in a predefined 
stereotactic (image) space (BRASS; Nuclear Diagnostics Ltd., Sweden). For a more detailed description of 
the methods for co-registration of SPECT receptor data using transmission images, the reader is referred to 
the paper of Van Laere and colleagues (2001). The sequential acquisition of transmission and emission 
images can be used to anatomically standardize the emission image using the same linear parameters as 
those used for the transmission image (Audenaert et al. 2003). The latter is first reoriented to a template in 
Talairach space and the same transformation is then given to the emission images. On the Talairach 
templates, a predefined volume-of-interest (VOI) set can be constructed (originally performed on perfusion 
SPECT images), which allows a user-independent sampling of the whole brain volume of different 
individuals without previously available structural information. All images were visually double-checked to 
ensure correct anatomical positioning of the predefined VOIs (Goethals et al. 2004). 
Radioactivity estimates in the cortex were assumed to represent total ligand binding (specific plus 
nonspecific binding plus free ligand) (Goethals et al. 2004). Because very few 5-HT2A receptors are present 
in the cerebellum, this region was chosen to represent nonspecific activity (Terriere et al. 1995). 
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Calculation of relative indices of specific BI was performed by VOI normalization to the activity per 
volume element in the cerebellum. Under these pseudo-equilibrium circumstances, BI is directly related to 
the in vivo receptor density (Bmax) and affinity (Kd). BI was defined as (target activity-background activity 
in the brain)/(background activity) which was operationally estimated as (counts/pixel in VOI- counts/pixel 
in the cerebellum)/(counts/pixel in the cerebellum) (Audenaert et al. 2003). 
Four bilateral cortical VOIs were defined and selected: the frontal cortex (FC), the temporal cortex 
(TC), the parietal cortex (PC) and the occipital cortex (OC). See also Fig 1 A. Because of our interest in the 
frontal cortical areas and the observed group differences in FC 5-HT2A receptor BI measurements, we 
further examined 5-HT2A receptor binding indices in separate frontal areas. The following four bilateral 
prefrontal cortical VOIs were defined: dorsal prefrontal cortex (DPFC), ventral prefrontal cortex (VPFC), 
orbitofrontal (OFC) cortex, and the anterior cingulate cortex (ACC). According to the BRASS program the 
DPFC consisted of the gyrus frontalis superior and the gyrus frontalis superior pars medialis. The VPFC 
consisted of the gyrus frontalis medius and the gyrus frontalis inferior. The OFC consisted of the gyrus 
rectus and the gyrus orbitalis. The ACC VOI consisted of the ventral and dorsal ACC. See also Fig 1 B. 
 
2.4. Statistical Methods 
 
All statistical analyses were performed with SPSS 15 (Statistical Package for the Social Sciences). 
Significance threshold was set at a two-tailed probability of p<.05 for all analyses. 
To compare group 5-HT2A receptor BI including the four cortical VOIs, in a first set of analyses 
the 5-HT2A receptor uptake values were analyzed as multiple dependent variables in a MANCOVA analysis 
with the four regions (VOI) as the dependent variables, group (ADN versus TRD patients versus never-
depressed controls) as the fixed between subjects factor, and age as covariate. For the univariate follow-up 
analyses of the omnibus MAN(C)OVA analyses we used Bonferroni corrected p-values for 4 comparisons. 
All further post hoc analyses were also Bonferroni corrected. 
In a second set of analyses, to compare group 5-HT2A receptor BI in the frontal cortex, these 
analyses were repeated with the four frontal VOIs. 
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In a last set of analyses confined to the TRD patients, we evaluated whether illness duration, 
SSRI/TCA last treatment before washout could influence 5-HT2A receptor BI patterns. These analyses were 
separately performed for the whole brain cortical VOIs and the frontal VOIs. 
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3. Results 
3.1. Group results. 
See Table 2 for an overview of the 5-HT2A receptor BI for the different groups.  
Mean HDRS scores for ADN depressed patients were 22.4±6.8 and 26.5±3.3 for TRD patients, 
indicating moderate to severe depression. Independent t-tests showed no significant differences in 
depression severity (t(28)=1.81, ns). A one-way ANOVA, with age as the dependent variable and group as 
the fixed factor, did not show significant group differences in age. 
 
3.1.1. Whole brain. 
The MANCOVA analysis, with the different cortical VOIs (FC, TC, PC, OC) as dependent 
variables, group (ADN versus TRD patients versus never-depressed controls) as the between group fixed 
factor, and age as covariate, showed that there were no significant effects implying the covariate age. 
Further, no significant group by region interaction effect was found. Therefore, age was excluded in further 
analyses. 
MANOVA analysis revealed a significant main effect of group (Wilks' Lambda: F(8,78)= 2.03, p< 
.05). The individual univariate tests (Bonferroni corrected) showed that the three groups differed 
significantly in 5-HT2A receptor BI in the FC (F(2,42)= 7.20, p< .01), but not for the TC  and OC. 
Bonferroni corrected post hoc analysis revealed that for the FC the 5-HT2A receptor BI in TRD patients was 
significantly lower (mean= 106.69) when compared to healthy controls (mean= 113.31) (p< .01). In TRD 
patients the 5-HT2A receptor BI in the FC was also significantly lower compared to the ADN patients 
(mean= 112.52) (p<.05). No significant difference in FC 5-HT2A receptor BI was observed between ADN 
patients and controls. See also Fig 2A. 
 
3.1.2. Frontal cortex. 
To evaluate 5-HT2A receptor binding indices in the separate frontal areas (DPFC, VPFC, OFC, 
ACC), as before, we first performed a MANCOVA analysis, with the different frontal cortical VOIs as the 
dependent variables, group (ADN versus TRD patients versus never-depressed controls) as the fixed factor, 
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and age as covariate. Again, this analysis showed that there was no significant contribution of the covariate 
age. Consequently, age was excluded in further analyses. 
MANOVA analysis revealed a significant main effect of group (Wilks' Lambda: F(8,78)= 2.32, p< 
.05). The individual univariate tests (Bonferroni corrected) showed that the three groups differed 
significantly in 5-HT2A receptor BI in the DPFC (F(2,42)= 8.11, p< .01) and the ACC (F(2,42)= 5.24, p< 
.05), but not for the VPFC and the OFC.  
Bonferroni corrected post hoc analysis showed that in the DPFC, TRD patients displayed 
significantly lower 5-HT2A receptor BI (mean= 105.44) compared to controls (mean= 111.96) (p<.01). 
TRD patients also displayed significantly lower 5-HT2A receptor BI compared to ADN patients (mean= 
112.53) (p<.05). The DPFC 5-HT2A receptor BI did not significantly differ between controls and ADN 
patients. Bonferroni post hoc analysis for the ACC also showed that the 5-HT2A receptor BI in TRD 
patients (mean= 106.00) was significantly lower compared to controls (mean= 114.55) (p< .05) and a trend-
like lower BI compared to ADN patients (mean= 112.56) (p= .07). No significant ACC 5-HT2A receptor BI 
differences were observed between controls and ADN patients. See also Fig 2B. 
 
3.2. 5-HT2A receptor BI results confined to the TRD patients. 
3.2.1. Whole brain. 
First, to examine whether illness duration of the current depressive episode in TRD patients 
influences 5-HT2A receptor BI measurements, again we performed a MANCOVA analysis, with the four 
different cortical VOIs as the dependent variables and duration of illness (in years) as covariate. This 
analysis showed that there was no significant contribution of the covariate illness duration. 
Second, to verify whether the last medication in the TRD patient group before washout could have 
influenced FC 5-HT2A receptor BI measurements, we compared patients with TCA washout (n=8) and 
patients without TCA washout (n=7). Independent t-tests showed no significant differences in 5-HT2A 
receptor BI between these two groups (t(13)= .71, ns). Age (t(13)=.02, ns), depression severity (t(13)=.24, 
ns) and gender (χ2 (1, n= 15) = .60, ns) were also not different between these two groups. Furthermore, we 
evaluated whether benzodiazepine treatment interfered with our measurements. Independent t-test showed 
no differences between those TRD patients under benzodiazepine treatment (n= 6) and those without 
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benzodiazepines (n= 9) in FC 5-HT2A receptor BI (t(13)=.45, ns), age (t(13)=.11, ns) or gender (χ2 (1, n= 
15) 2.27, ns). Because of the small sample size, we also applied non-parametric Mann-Whitney U tests to 
evaluate the influence of TCA treatment on 5-HT2A receptor BI measurements. Again no significant group 
differences were observed for the FC. Mann-Whitney U tests also did not reveal significant benzodiazepine 
influences in FC 5-HT2A receptor BI. 
 
3.2.2. Frontal cortex. 
To evaluate whether illness duration of their current depressive episode might influence 5-HT2A 
receptor BI measurements in the frontal cortex, we performed a MANCOVA analysis, with the four 
different frontal cortical VOIs as the dependent variables and duration of illness (in years) as covariate. 
This analysis again showed no significant contribution of the covariate illness duration. 
To verify whether the last medication before washout might have influenced 5-HT2A receptor BI 
measurements, again we compared TRD patients with TCA washout (n=8) and patients without TCA 
washout (n=7). Independent t-tests showed no significant differences in 5-HT2A receptor BI between these 
two groups for the DPFC (t(13)=1.10, ns) nor for the ACC (t(13)=.97, ns). To examine whether the use of 
benzodiazepines could have been a confounding factor, independent t-tests did not demonstrate 5-HT2A 
receptor BI differences for the DPFC (t(13)=1.25, ns) nor for the ACC (t(13)=.85, ns). We also applied the 
non-parametric Mann-Whitney U tests to evaluate the influence of current TCA treatment on 5-HT2A 
receptor BI measurements. No significant group differences were observed for the DPFC and the ACC. 
Mann-Whitney U tests confirmed the lack of benzodiazepine confounds on 5-HT2A receptor BI for the 
DPFC and the ACC. 
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4. Discussion 
 In agreement with our initial hypothesis, TRD patients displayed significantly less frontal cortical 
5-HT2A receptor binding indices compared to controls. Compared to ADN patients, treatment resistant 
depression was also characterized by lower 5-HT2A receptor BI. In contrast to our initial hypothesis, no 
significant differences in cortical 5-HT2A receptor BI between ADN patients and never-depressed healthy 
controls were observed. Compared to both other groups, TRD patients displayed significantly less 5-HT2A 
receptor BI specifically in the DPFC and, at a trend level, also in the ACC 
 Our observations in ADN patients are nevertheless in line with the Schins et al (2005) study, 
which also found no significant differences in 5-HT2A receptor binding when AD-naïve post-myocardial 
depressed patients were compared a non-depressed healthy group. However, our results do not support the 
observations of Messa et al (2003), who reported that symptomatic ADN patients showed decreases in 
frontal cortical 5-HT2A binding indices compared to their control group. Although not explicitly mentioned, 
it could be possible that the heterogeneous sampling of depressed patients could have introduced more 
variability in their data. Further, some ADN patients had experienced one to three depressive episodes in 
the past whereas our ADN patients were all first episode patients. The lack of differences in 5-HT2A 
receptor BI between healthy controls and ADN patients could indicate that melancholic depression might 
not be directly related to alterations in frontal cortical 5-HT2A receptor BI in first episode depressed 
patients.  
Concerning the results in our TRD patient group, one could argue that the observed 5-HT2A 
receptor BI decreases in the frontal cortex in the TRD patient group are merely the result of long-term AD 
therapy (Van Oekelen et al. 2003). Given that our first episode ADN individuals, with a similar subtype of 
depression, showed no differences in 5-HT2A BI compared to healthy controls we cannot exclude the 
possibility that the differences between ADN and TRD group are due to treatment exposure rather than 
depression itself. However, Messa et al (2003) studied a group of antidepressant naive depressed patients 
(thus without treatment exposure) who had from 0 to 3 former depressive episodes and they also showed 
decreased 5-HT2A BI compared to healthy controls. Moreover, if this would have been the case this 
decrease in 5-HT2A receptor BI should also have been present in the other examined cortical areas. For 
instance, Bhagwager et al (2006) found in a sample of 6 month medication-free formerly depressed 
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euthymic patients that recovery from depression resulted not only in a prefrontal increase of 5-HT2A 
receptor binding but also in the parietal and occipital cortices. Furthermore, in our study illness duration of 
the current depressive episode did not influence 5-HT2A receptor BI measurements in none of the VOIs 
examined. As mentioned before, during the current depressive episode all our TRD patients failed to show 
response after at least three well carried-out pharmacological trials, including non-response to SSRI/NSRIs 
and TCAs. Importantly, the influence of the last AD treatment before washout had no significant effect on 
5-HT2A receptor BI measurements. Half of our TRD patients were not on TCA treatment before washout 
and frontal cortical 5-HT2A receptor binding indices were not significantly different from those who had 
received TCA treatment as last unsuccessful pharmacological intervention. In addition to the 5-HT2A 
receptor down-regulation associated with successful TCA treatment (Van Oekelen et al. 2003), it has been 
shown that successful treatment response with SSRI and electroconvulsive shock therapy (ECT) was 
associated with prefrontal 5-HT2A receptor up-regulation (Massau et al. 1997; Burnet et al. 1999; Zanardi et 
al. 2001). Another confounding factor could have been the use of benzodiazepines in the TRD patient 
group. However, our analyses did not suggest such a possible influence on 5-HT2A receptor BI in the 
cortical areas examined. Indeed, not all studies demonstrated an impact of these psychotropic drugs 
(Leysen et al. 1987; Messa et al. 2003), and if they did, instead of a down-regulation, an up-regulation of 5-
HT2A receptors could be expected (Zanardi et al. 2001; Akin et al. 2004). Since increased 5-HT2(A) receptor 
BI has been reported post-mortem in the frontal cortices of suicide victims (van Heeringen et al. 2003), it is 
also important to point-out that no suicide attempt had occurred in our sample at least 6 months prior to this 
study. 
Our results could imply that the reduced cortical 5-HT2A receptor binding found in melancholic 
TRD patients might be specific for the underlying pathophysiological state of the disease. This assumption 
is also in line with the prefrontal neurodegenerative effects due to hypercortisolaemia in long-term 
melancholically depressed states (Porter & Gallagher 2006).  
To further elucidate the impact of treatment resistance in melancholic depression, we further 
examined the 5-HT2A receptor BI within these frontal cortical areas. Compared to controls and ADN 
patients, significant reductions in the DPFC and ACC 5-HT2A receptor BI in TRD patients were observed.  
Interestingly, other types of brain imaging studies, not all related to the serotonergic neurotransmitter 
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system, reported on dysfunctional ‘fronto-cingulate networks’ frequently found in major depressive 
disorder (Mayberg 2003; Drevets et al. 2008; Pizzagalli 2011). Besides prefrontal decreases in neuronal 
activity, decreased ACC activation patterns have frequently been documented (Davidson et al. 2002). In 
major depression dorsal prefrontal-cingulate cortical abnormalities have been commonly observed, in 
particular during emotional processing and cognitive control (Drevets et al. 2008). These cognitive 
processes are in particular problematic for depressed patients (Mayberg 2003). Our observations of a lower 
DPFC-ACC 5-HT2A receptor BI in TRD patients might indicate a specific cognitive control problem during 
emotional processing in patients with increasing vulnerability for depression after multiple episodes (De 
Raedt & Koster 2010). Furthermore, the observation that healthy controls and ADN depressed patients did 
not show different 5-HT2A receptor BI in these areas suggests that possible cognitive control problems 
would not be significantly present during a first depressive episode.  However, as we did not integrate 
neurocognitive tasks in our design these assumptions must be interpreted cautiously. 
Although our findings could suggest specific neurobiological abnormalities for treatment resistant 
melancholic depression, at this point these assumptions remain to some extent speculative as this study is 
limited by some methodological issues. Besides that the sample size is relatively small, the antidepressant-
free period of two weeks after washout could be interpreted as relatively short, in spite that this extent of 
time is in range with other unipolar depressed patient studies examining 5-HT2A receptors (D’haenen et al. 
1992; Meyer et al. 1999; Van Oekelen et al. 2003). Although the main goal of this study was to investigate 
treatment-resistance in melancholic depressed patients by examining the 5-HT2A receptor BI, at this point 
we cannot predict who in the end of our ADN patients will be a stage III AD non-responder. Albeit 
statistically this should be around 10-15% of this group, this could have introduced some bias in our 5-
HT2A receptor BI measurements. However, the fact that we observed a significant  difference between the 
TRD and the ADN patients despite that a part of the ADN group might reveal to be also treatment resistant 
is indicative of the magnitude of the effect. 
In conclusion, our observations indicate that on the cortical level 5-HT2A receptor binding indices 
do not significantly differ in first-episode melancholic depressed patients compared to healthy controls, at 
least indicating a limited short-term impact on the serotonergic system when first-time currently depressed. 
Further, our results suggest that when challenged with treatment resistance the DPFC-ACC neurocircuitry 
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is significantly more affected when compared to currently depressed ADN patients or controls. Whether 
this assumed underlying pathophysiological mechanism is due solely to abnormalities in the serotonergic 
system remains to be answered. It is possible that the long-term depressive episodes present in our TRD 
group could have resulted in reduced serotonergic innervations and/or atrophy in the frontal cortical 
regions, reflected by the lower 5-HT2A receptor BI. Importantly, all interpretations should be limited to 
depressed patients of the melancholic subtype. Future 5-HT2A receptor BI studies might do well to combine 
brain imaging with executive functioning tests, BDNF measurements or structural MRI to further unravel 
the underlying payhophysiology of treatment resistance in well-defined groups of majorly depressed 
samples. This comparison will be central for differentiating the two groups and for ascertaining the role of 
prefronto-cingulate 5-HT2A receptor BI in conferring treatment resistant in melancholic unipolar 
depressives. Importantly, as the hippocampus has been put forward as a target region to investigate in 
‘serotonin’ research (Fujita et al. 2000), future research should also focus on possible hippocampal 5-HT2A 
receptor abnormalities in first episode depressed patients as well as in patients unresponsive to current 
pharmacological algorithms. 
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TRD 
Patient 
Gender Age Thase and Rush 
stage 
Duration current 
episode (years) 
HDRS  Last antidepressant 
medication before washout 
Benzodiazepines
(dose/day) 
1 F 45 3 3 32 Duloxetine Clonazepam 1mg 
2 F 49 3 3  32 Amytriptiline Lormetazepam 2 mg 
3 F 32 3 2 29 Venlafaxine Alprazolam 2 mg 
4 F 47 3 12  30 Amytriptiline Bromazepam 24mg 
5 F 42 3 4 23 Clomipramine no 
6 F 50 3 4 27 Nortryptiline no 
7 F 52 3 5  23 Amytriptiline no 
8 F 45 3 1.5  25 Dosulepine Flunitrazepam 1mg 
9 F 48 3 5  26 Venlafaxine no 
10 M 25 3 2  22 Clomipramine no 
11 M 40 4 2.5  26 Paroxetine Alprazolam 1mg 
12 M 34 3 11 23 Clomipramine no 
13 M 39 3 1  27 Clomipramine no 
14 M 34 5 7  21 Fenelzine no 
15 M 54 4 4 27 Fenelzine no 
        
Mean (SD)  38.55 (9.53)  4.47 (3.25) 26.53 (3.29)   
Table 1:  Demographic data of the treatment resistant group of melancholic depressed patients (TRD). HDRS: 17- item 
Hamilton Depression Rating Scale. F: female. M: male. SD: standard deviation. 
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VOI Healthy controls ADN patients TRD patients 
    
Prefrontal cortex 113.31 (4.39) 112.52 (4.73) 106.39 (6.32) 
Temporal cortex 110.16 (4.26) 109.49 (4.44) 107.49 (5.17) 
Parietal cortex 109.76 (6.44) 109.88 (5.67) 108.12 (6.67) 
Occipital cortex 111.18 (7.49) 110.53 (7.81) 107.52 (4.72) 
    
Dorsoprefrontal 
cortex 
111.96 (4.45) 112.53 (4.64) 105.44 (6.70) 
Ventroprefrontal 
cortex 
112.62 (4.88) 112.00 (5.42) 108.06 (4.64) 
Orbitofrontal cortex 114.71 (7.28) 113.02 (7.19) 106.94 (11.21) 
Anterior cingulate 
cortex 
114.55 (8.55) 112.56 (7.63) 106.00 (6.37) 
    
 
 
Table 2. Means and standard deviations of 5-HT2A receptor binding indices in the different volumes of 
interest (VOI) examined.  
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Fig 1: Overview of the different volumes of interest (VOI). For a more detailed description of the VOIs see 
text. 
A) Cortical brain VOIs. Axial views (Z= -10 and 55). Sagittal view (X= 0). Dark red: frontal cortex (FC), 
Violet: temporal cortex (TC), Cyan: parietal cortex (PC), Dark green: occipital cortex (OC). 
B) Prefrontal cortical VOIs. Axial views (Z= -12 and 5). Sagittal view (X= 0).  Green: Red: dorsal 
prefrontal cortex, Green: anterior cingulate cortex, Blue: orbitofrontal cortex, Yellow: ventral prefrontal 
cortex.  
a= anterior, p= posterior, L= left, R= right. 
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Fig 2 A. Results of the cortical brain VOIs represented in bar graphs. FC= frontalcortex, TC= temporal 
cortex, PC= parietal cortex ,OC= occipital cortex. 
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Fig 2 B. Results of the prefrontal cortical VOIs represented in bar graphs. DPFC= dorsal prefrontal 
cortex, VPFC= ventral prefrontal cortex ,OFC= orbitofrontal cortex, ACC= anterior cingulate cortex.  
 (*) significant different group effects at a two-tailed probability of p< .05. ADN= antidepressant naïve. TRD= treatment 
resistant depression. BI= Binding Index. 
